Your browser doesn't support javascript.
loading
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
Alcalá, Carmen; Gascón, F; Pérez-Miralles, F; Gil-Perotín, S; Navarré, A; Boscá, I; Coret, F; Casanova, B.
Afiliación
  • Alcalá C; Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain. mc.alcalavicente@gmail.com.
  • Gascón F; Unit of Neuroimmunology, Department of Neurology, Hospital Clínico Universitario, Valencia, Spain.
  • Pérez-Miralles F; Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
  • Gil-Perotín S; Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
  • Navarré A; Unit of Neuroimmunology, Department of Neurology, Hospital Clínico Universitario, Valencia, Spain.
  • Boscá I; Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
  • Coret F; Unit of Neuroimmunology, Department of Neurology, Hospital Clínico Universitario, Valencia, Spain.
  • Casanova B; Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
J Neurol ; 265(7): 1690-1697, 2018 Jul.
Article en En | MEDLINE | ID: mdl-29785523
INTRODUCTION: Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). OBJECTIVE: To investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. RESULTS: A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% (p < 0.001). A significant decrease of EDSS to 4.6 was observed (p = 0.01) after 1 year of treatment, which remained stable during the second year in both groups. There was no evidence of disease activity in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. Infusion-related symptoms were the most prevalent side effect (18.8%) and most were mild. Three thrombotic events were detected. CONCLUSION: Rituximab could be an effective and safe treatment in aggressive RRMS. Some selected PMS patients could also benefit from this treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Rituximab / Factores Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Neurol Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Rituximab / Factores Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Neurol Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Alemania